Peptides for Cardiovascular Biology
Reviewed by Marcus Hopkin, PhD
Director of Research and Development, Volta Peptides
Written by Volta Peptides Editorial Team · Reviewed September 15, 2026
This guide explores two prominent peptides currently under investigation for their roles in cardiovascular biology. These peptides are assessed based on the strength of available evidence, ranging from those with established clinical applications to those still in early research phases. Each compound is analyzed for its underlying mechanisms, safety profiles, and current clinical status, providing a comprehensive overview for researchers interested in cardiovascular therapeutics.
Overview
2 research peptides are currently studied for cardiovascular biology. This guide ranks them by evidence strength and covers their mechanisms, safety profiles, and current clinical status.
Endothelin-1 — Well-Characterized / ERA Drugs Approved
Evidence Rating: B
Category: Cardiovascular / Vasoactive
Endothelin-1 (ET-1) is a potent 21-amino-acid peptide (MW ~2491.9 g/mol) predominantly synthesized by vascular endothelial cells. It is recognized as the most powerful endogenous vasoconstrictor, with effects that can persist for several hours. Research indicates that the ET-1 signaling pathway plays a pivotal role in the pathogenesis of pulmonary arterial hypertension (PAH), making it a critical target for therapeutic intervention.
Clinical studies have led to the development of endothelin receptor antagonists (ERAs), such as bosentan and ambrisentan, which have received FDA approval for the treatment of PAH. These agents have demonstrated efficacy in improving exercise capacity and reducing clinical worsening in patients. However, while the ET-1 pathway is well-characterized, challenges remain regarding the long-term safety and potential side effects associated with ERA therapies, necessitating ongoing research to optimize their use in clinical practice.
Angiotensin 1-7 — Preclinical / Early Research
Evidence Rating: D
Category: Cardiovascular / Vasoactive
Angiotensin 1-7 is a 7-amino-acid peptide (sequence: Asp-Arg-Val-Tyr-Ile-His-Pro, MW ~899.0 g/mol) generated primarily through the ACE2-mediated cleavage of angiotensin II. This peptide serves as a counter-regulatory component of the renin-angiotensin system, opposing the vasoconstrictive and pro-inflammatory effects typically associated with angiotensin II. Research suggests that angiotensin 1-7 may promote vasodilation and contribute to lower blood pressure, potentially offering cardioprotective effects in various animal models of heart failure.
Despite its promising biological activities, angiotensin 1-7 remains largely in the preclinical stage, with limited clinical data available to support its therapeutic application. As of now, there are no approved indications for angiotensin 1-7, highlighting the need for further investigation into its safety and efficacy in human populations. Studies are ongoing to elucidate its role in cardiovascular health and disease, aiming to clarify its potential as a therapeutic target.
Shop Research Peptides
Cagrilintide 5mg
DSIP 10mg
Epithalon 10mg
GHRP-2 5mg
5mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Peptide Tools
Key research references
- Best Peptides for Anti-Aging | Research Guide
- Best Peptides for Metabolic Health | Research Guide
- Best Peptides for Weight Management | Research Guide
- Best Peptides for Body Composition | Research Guide
- Best Peptides for Reproductive Health | Research Guide
- Best Peptides for Anti-Aging & Longevity | Research Guide
- Best Peptides for Weight Loss | Research Guide
- Best Peptides for Cognitive Enhancement | Research Guide
- Retatrutide Dosing Guide | Protocols & Reconstitution
- Wound Healing Peptides | Research Compounds
- Muscle Growth Peptides | Research Compounds
- Immune Modulation Peptides | Research Compounds
Browse the research catalogue
Buying and verification
Frequently Asked Questions
Related Resources
Related Research
About the reviewer
Director of Research and Development, Volta Peptides
Marcus Hopkin, PhD, is Director of Research and Development at Volta Peptides. He has more than 12 years of analytical chemistry experience, including direct laboratory work in peptide synthesis, characterization, purity testing and stability assessment. His doctoral research at the University of Michigan examined novel peptide structures in the human proteome and their potential significance for therapeutic-peptide research. Before joining Volta Peptides he held research and development roles at Amgen and Eli Lilly and Company, and served as a lecturer at the University of Michigan.
Marcus reviewed this article for scientific and analytical accuracy on September 15, 2026. He did not write it. Technical review is internal review and is not peer review, independent third-party review or medical review.
Disclosure. Marcus Hopkin is an employee of Volta Peptides and serves as its Director of Research and Development. Volta Peptides sells research compounds related to subjects discussed in the content he writes and reviews. His reviews are internal scientific and technical review and must not be described as independent third-party review, peer review or medical review.